AstraZeneca Earlier Reported Q1 EPS $0.82 Beats $0.75 Estimate, Sales $7.32B Beat $7.08B Estimate
AstraZeneca (NYSE:AZN) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.75 by 9.33 percent. This is a 21.9 percent decrease over earnings of $1.05 per share from the same
Earnings Scheduled For April 30, 2021
Companies Reporting Before The Bell
• O2Micro Intl (NASDAQ:OIIM) is estimated to report quarterly earnings at $0.09 per share on revenue of $23.30 million.
Pfizer Said To Have Begun Exporting US-Made COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) has started exporting COVID-19 vaccine doses produced in its U.S.
Pfizer-BioNTech Bullish On COVID-19 Vaccine Trial Results In Infants By September: Reuters
BioNTech SE's (NASDAQ: BNTX) CEO Ugur Sahin says the company, along with its partner Pfizer Inc (NYSE: PFE), could have data from trials…
AstraZeneca’s MEDI5884-PCSK9 Inhibitor Combo Shows Promise In Heart Disease
Most heart disease drugs are aimed at reducing the "bad" low-density lipoprotein (LDL) cholesterol. However, strategies related to cutting LDL cholesterol and increasing high-density lipoprotein (HDL) cholesterol are of interest in combating the risk of heart disease.
Johnson & Johnson Set To Resume COVID-19 Vaccine Rollout In Europe — With A Warning On The Label
Johnson & Johnson (NYSE: JNJ) said Tuesday that the European rollout of its COVID-19 vaccine is set to continue after it got the go-ahead from the regulator on the continent.
Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study
iocartis Group NV today announces that it has entered into a master collaboration agreement with AstraZeneca (NYSE:AZN). The…
7 Blockbuster Drugs Expected To Be Launched In 2020
Biotech stocks had a fairly decent run in 2019, thanks to record deal flow, several path-breaking innovation in…